Harpreet has nearly 15 years of experience as a Research and Development leader in fast-paced industrial settings across the pharmaceutical, biotechnology and cannabis sectors. Before joining PharmAla, Harpreet was the Director of research and development for one of the world’s largest medical cannabis companies. During this time, she nurtured her exceptional technical skills across clinical development, commercialization and regulatory affairs helping Tilray register and launch products across the EU, AUS and USA. Before her work with Tilray, she worked for some of the biggest pharmaceutical companies, such as Sun Pharma, IPCA Labs and Biocon Ltd.
PharmAla Biotech is a Canadian drug discovery & development company that is a regulatory first organization focused on advancing the research of MDMA and MDXX series of compounds. To ensure that researchers across the globe have a steady supply of clinical-grade MDMA, PharmAla has also developed a robust supply chain with well-established, GMP-certified manufacturing sites in Canada.
As Vice President of Research, Harpreet is responsible for identifying new analogs of MDMA that retain the efficacy but have a substantially improved safety profile. She oversees the chemistry, manufacturing and pre-clinical research to advance the MDXX series of molecules.